Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoromethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL6086977 | 1.00 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL63150 | 0.96 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL6682798 | 0.96 | CA1 (0.44) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL4930505 | 0.92 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL20678154 | 0.92 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL7636486 | 0.92 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL5795370 | 0.92 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL7641565 | 0.92 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL7637460 | 0.92 | CA1 (0.41) | CA1CA2CA7CA13GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL8639691 | 0.92 | CA1 (0.41) | CA1CA2CA7CA13GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798219-A | Preparation method of octreonazole | 长治医学院 | 2025-04-11 | — | — | CN | claimed |
| CN-108821974-B | Preparation method of alkoxy acrylate | 中国科学院兰州化学物理研究所 | 2020-10-27 | — | — | CN | claimed |
| US-9718919-B2 | Radically polymerizable polyether, method for producing said radically polymerizable polyether, polymerizable composition comprising said radically polymerizable polyether and radically polymerizable vinyl monomer, and copolymer, molded article and film each formed by radical polymerization of said polymerizable composition | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-08-01 | — | — | US | claimed |
| EP-2748224-B1 | METHOD OF PRODUCING HIGH VOLTAGE ELECTRICAL INSULATION | ABB RESEARCH LTD (CH) | 2017-07-05 | — | — | EP | claimed |
| US-20160002399-A1 | RADICALLY POLYMERIZABLE POLYETHER, METHOD FOR PRODUCING SAID RADICALLY POLYMERIZABLE POLYETHER, POLYMERIZABLE COMPOSITION COMPRISING SAID RADICALLY POLYMERIZABLE POLYETHER AND RADICALLY POLYMERIZABLE VINYL MONOMER, AND COPOLYMER, MOLDED ARTICLE AND FILM EACH FORMED BY RADICAL POLYMERIZATION OF SAID POLYMERIZABLE COMPOSITION | MITSUBISHI RAYON CO., LTD. (JP) | 2016-01-07 | — | — | US | claimed |
| US-20140329023-A1 | METHOD OF PRODUCING HIGH VOLTAGE ELECTRICAL INSULATION | ABB RESEARCH LTD. (CH) | 2014-11-06 | — | — | US | claimed |
| EP-2748224-A1 | METHOD OF PRODUCING HIGH VOLTAGE ELECTRICAL INSULATION | ABB Research Ltd. (CH) | 2014-07-02 | — | — | EP | claimed |
| WO-2013034193-A1 | METHOD OF PRODUCING HIGH VOLTAGE ELECTRICAL INSULATION | ABB RESEARCH LTD (CH) | 2013-03-14 | — | — | WO | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4716532-A2 | BICYCLIC HETEROARYL COMPOUNDS | Quantx Biosciences US, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-12577201-B2 | Glutamine analogs | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4229029-B1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2026-02-25 | — | — | EP | disclosed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| CN-1310709-A | N, N-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2001-08-29 | — | — | CN | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
| JP-2000073014-A | 2-CYANOACRYLATE-BASED COMPOSITION | TOAGOSEI CO LTD | 2000-03-07 | — | — | JP | disclosed |
| US-5874595-A | SINGLE STEP, SELECTIVE ACETYLATION OF 10-DEACETYLBACCATIN III INTO BACCATIN III USING LEWIS ACID CATALYSTS IN THE REACTION WITH ACETIC ANHYDRIDE; PREPARATION OF TAXOL FROM BACCATIN III | PHARMACHEMIE B.V. (NL) | 1999-02-23 | — | — | US | disclosed |
| EP-0875508-A1 | Method for the preparation of baccatin III and derivatives thereof from 10-deacetylbaccatin III | PHARMACHEMIE B.V. (NL) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577201-B2 | Glutamine analogs | GLUL, GLS, GLS2 | ACHE 2119/4885CA1 2255/4885CA2 2918/4885 |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | AIFM2, GPX1, SOD1 | ACHE 3880/4885CA1 1020/4885CA2 1110/4885 |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | AIFM2, GPX1, GPX4 | ACHE 4879/4885CA1 1600/4885CA2 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.